Read this manager's filing book
Disclosed positions
Sivik Global Healthcare LLC: source evidence dated 2026-07-21T03:59:59.999Z.
- Issuer
- STATE STREET SPDR S&P BIOTECH
- Ticker
- XBI
- Class
- S&P BIOTECH
- Reported value
- $19,160,000
- Reported amount
- 150,000
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001596452-26-000004Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| STATE STREET SPDR S&P BIOTECH | XBI | S&P BIOTECH | $19,160,000 | 150,000 | SH | None |
| CARDINAL HEALTH | CAH | COM | $5,071,000 | 24,000 | SH | None |
| CALL- BSX 100 @ 75 EXP 04/17/2026 | Unresolved | CALL | $5,020,000 | 800 | SH | None |
| JOHNSON&JOHNSON | JNJ | COM | $4,889,000 | 20,000 | SH | None |
| MERCK & CO | MRK | COM | $4,812,000 | 40,000 | SH | None |
| CENCORA INC | COR | COM | $4,712,000 | 15,000 | SH | None |
| ELI LILLY & CO | LLY | COM | $4,599,000 | 5,000 | SH | None |
| WATERS CORP | WAT | COM | $4,467,000 | 15,000 | SH | None |
| VERTEX PHARMACEUTICALS INC. | VRTX | COM | $4,465,000 | 10,000 | SH | None |
| INTUITIVE SURG | ISRG | COM NEW | $4,149,000 | 9,000 | SH | None |
| ASTRAZENECA PLC | AZN | ORD | $3,944,000 | 20,000 | SH | None |
| THERMO FISHER SCIENTIFIC INC. | TMO | COM | $3,932,000 | 8,000 | SH | None |
| BOSTON SCIENTIFIC CORPORATION | BSX | COM | $3,891,000 | 62,000 | SH | None |
| DANAHER CORP | DHR | COM | $3,792,000 | 20,000 | SH | None |
| TENET HEALTHCARE | THC | COM NEW | $3,774,000 | 20,000 | SH | None |
| GILEAD SCIENCES INC | GILD | COM | $3,484,000 | 25,000 | SH | None |
| HUMANA INC. | HUM | COM | $3,468,000 | 20,000 | SH | None |
| METTLER TOLEDO | MTD | COM | $3,468,000 | 2,750 | SH | None |
| MCKESSON CORP | MCK | COM | $3,461,000 | 4,000 | SH | None |
| AGILENT TECHNOLOGIES INC | A | COM | $3,419,000 | 30,000 | SH | None |
| STRYKER CORP | SYK | COM | $3,286,000 | 10,000 | SH | None |
| ABBVIE INC | ABBV | COM | $3,262,000 | 15,000 | SH | None |
| UNIV HEALTH SVC | UHS | CLASS B | $3,132,000 | 17,500 | SH | None |
| REGENERON PHARMACEUTICALS | REGN | COM | $3,091,000 | 4,000 | SH | None |
| BIO-RAD LABS A | BIO | CL A | $2,788,000 | 10,000 | SH | None |
| BIOGEN INC | BIIB | COM | $2,750,000 | 15,000 | SH | None |
| UNITEDHEALTH GRP | UNH | COM | $2,706,000 | 10,000 | SH | None |
| GLOBUS MEDICAL | GMED | CL A | $2,585,000 | 30,000 | SH | None |
| ABBOTT LABS | ABT | COM | $2,567,000 | 25,000 | SH | None |
| EDWARDS LIFESCIENCES | EW | COM | $1,602,000 | 20,000 | SH | None |
| SMITH & NEPHEW | SNN | SPDN ADR NEW | $1,589,000 | 50,000 | SH | None |
| ELEVANCE HEALTH INC | ELV | COM | $1,464,000 | 5,000 | SH | None |
| ENCOMPASS HEALTH CORP | EHC | COM | $1,451,000 | 15,000 | SH | None |
| CVS HEALTH CORP | CVS | COM | $1,436,000 | 20,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.